Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2025 Jul 29.
Published in final edited form as: Angew Chem Int Ed Engl. 2025 Jul 21;64(36):e202509674. doi: 10.1002/anie.202509674

A C-to-B Atom Swap on Coumarins and Dibenzolactones

Tian You 1,+, Quang H Luu 1,+, Junqi Li 1,*
PMCID: PMC12306449  NIHMSID: NIHMS2099008  PMID: 40685870

Abstract

We report a carbon-to-boron “C-to-B” atom swap reaction to transform readily available coumarins into their isosteric benzoxaborins via a net replacement of the C=O group with a B–OH moiety. These conditions were applied to coumarin natural products and other 6–7-membered lactones (25 examples, 29%–93%). We leverage this methodology to transform a flat polyaromatic hydrocarbon into three-dimensional tribenzo[b.d.f]oxepines through a series of atom-swapping reactions followed by ring expansion via the oxaborin intermediate.

Keywords: Atom swapping, Boronic ester, Coumarin, Decarbonylation, Nickel catalysis

Graphical Abstract

graphic file with name nihms-2099008-f0001.jpg

Cyclic boronic hemiesters, boron isosteres of lactones, display unique and valuable chemical properties. Herein, we report a novel method for their synthesis via nickel-catalyzed decarbonylative borylation, enabled by electron-rich phosphine ligands to achieve a formal “C-to-B” atom swap. This strategy efficiently transforms a variety of coumarin derivatives and seven-membered dibenzolactones into the corresponding benzoxaborines, showcasing broad functional group tolerance and synthetic versatility.


Cyclic boronic hemiesters are boron isosteres of lactones. In medicinal chemistry, the isosteric relationship between the boronic acids and esters has been utilized to great effect in the design of Lewis acidic transition state analog inhibitors that bind to critical nucleophilic residues in the active site of enzymes.[1] Furthermore, the variety of intra- and intermolecular interactions[2] by which cyclic boronic esters such as QPX7728 and Tavaborole engage their biological targets have made them increasingly valuable in drug discovery efforts (Figure 1a).[3–6] As synthetic intermediates, cyclic boronic hemiesters are known to be competent coupling partners in Suzuki–Miyaura cross-coupling reactions,[7–9] as precursors to (benzo)coumarins,[9–11] and as boron enolates.[12] The development of new approaches to rapidly access these compounds thus stands to advance their applications in medicinal chemistry and downstream methodology development.

Figure 1.

Figure 1.

a) The medicinal chemistry of boronic acids and esters arises from their ability to bind to nucleophilic residues. b) Recent strategies for benzoxaborin synthesis. c) This work.

A few synthetic approaches already exist for the synthesis of oxaborins (6-membered cyclic boronic hemiesters),[7–23] the most common method being the borylation of an aryl or vinyl halide, followed by cyclization of the pendant phenol onto the newly-installed boron center.[7,8] In recent patent literature,[24] the boron-Wittig reaction was utilized to access oxaborin structures (Figure 1b). Yorimitsu and coworkers undertook an “aromatic metamorphosis” approach by converting benzofurans into benzoxaborins by Ni-catalyzed boron insertion.[10,11] In this work, we report a conceptually distinct carbon-to-boron “atom swap” strategy to access benzoxaborins from their more abundant[25,26] carbon isosteres (Figure 1c). During the course of our manuscript revision, a report on a carbonyl-to-boranyl exchange on aromatic lactones was recently published.[27]

We previously demonstrated that lactones are viable precursors to phosphine-ligated Ni(aryl)(aryloxo) metallacycles (Figure 2a) in our development of a carbon-to-oxygen (“C-to-O”) atom swapping reaction sequence.[28] C–O reductive elimination from these and related intermediates[28,29] can be challenging. We thus reasoned that intercepting these Ni(aryl)(aryloxo) intermediates by transmetalation with a bisboron reagent would form the required C–B bond. The proposed catalytic cycle would proceed via the oxidative addition of Ni(0) into the acyl C–O bond in coumarin 1a, CO deinsertion, followed by transmetallation with a B2(OR)4 reagent with the pendant aryloxo ligand acting as an internal base, and reductive elimination to furnish a bisboron intermediate 2a-B (Figure 2b). Acidic work-up would then generate the desired oxaborin. Accomplishing this transformation would also establish coumarins as viable electrophiles by C(acyl)–O bond activation by Ni catalysts.

Figure 2.

Figure 2.

a) Esters as precursors to Ni(aryl)(aryloxo) intermediates. b) Proposed catalytic cycle for a nickel-catalyzed decarbonylative–borylation reaction.

We started the investigation by evaluating ligands for the proposed decarbonylative borylation on coumarin 1a. After a set of ligand screening, P(nBu)3 turned out to be the optimal ligand for the desired transformation. Other monodentate phosphine ligands that were bulkier or less electron-rich gave no to low yields (see Supporting Information for full optimization details). It is worth noting that the IPr ligand could also give a competitive yield, showing the potential of the N-heterocyclic carbene (NHC) ligands in promoting such transformations. We also evaluated different bisboron reagents, which had a significant impact on the borylation reaction. The commonly used B2nep2 and B2pin2 were less effective than B2eg2 (Figure 3, entries 7 and 10, 35% and 36%, respectively). Other bisboron reagents that are bulkier and/or with lower Lewis acidity than B2eg2 gave lower yields (Figure 3, entries 8 and 9), presumably due to their lower reactivity in transmetallation.[30,31] However, the more electron-deficient B2cat2 was also an unsuitable borylating reagent.

Figure 3.

Figure 3.

Reaction optimization. Reaction conditions: 1a (0.200 mmol), Ni(cod)2 (0.040 mmol, 20 mol%), ligands (40 mol% for monodentate, 20 mol% for bidentate), B2(OR)4 (0.240 mmol, 1.2 equiv), xylene (1.0 mL, 0.20 M). a)Isolated yield was obtained as described in the Supporting Information. b)Ni(cod)2 was replaced by Pd2(dba)3. c)1.5 equiv. Na2CO3 was added.

The Ni(cod)2/P(nBu)3 catalyst derived from our optimization studies is consistent with the use of nickel complexes bearing strong σ-donating ligands in Ni-catalyzed intermolecular decarbonylative borylation of esters by the Shi and Rueping groups.[32,33] However, directly applying the reported reaction conditions to 1a gave no detectable yields of 2a. Furthermore, we found that the addition of base, which is often used to promote transmetalation, led to a lower yield of 2a, highlighting the nuances of developing seemingly similar decarbonylative transformations on different substrates.

The optimal conditions were then applied to transform a collection of coumarins, including natural products and fluorophores, into their boron isosteres (Figure 4). Common substituents on the benzene ring of coumarin natural products were tolerated. For instance, a C-to-B swap on toncarine, a food additive and fragrance,[34] resulted in a 93% yield of 2b. Derivatives of umbeliferone gave 68% and 84% yields of the corresponding benzoxaborins 2c and 2d, respectively. A C-to-B swap on the pharmaceutical NSC31868 resulted in a 41% yield of the product 2e. 5,7-dimethoxy substituted coumarin 2f gave a modest 38% yield, but a higher 47% yield was obtained when the ligand was switched to dcype.

Figure 4.

Figure 4.

Scope of the C-to-B swap. Reaction condition: 1 (0.200 mmol), Ni(cod)2 (0.040 mmol, 20 mol%), ligand (40 mol% for P(nBu)3, 20 mol% for dcype), B2eg2 (0.240 mmol, 1.2 equiv.), xylene (1.0 mL, 0.20 M). Isolated yields were obtained as described in the Supporting Information.

The borylation of 4-substituted coumarins 2g–2l could not be effectively promoted by the Ni/P(nBu)3 catalytic system. However, switching the ligand from P(nBu)3 to dcype significantly improved the reaction yield to 61% for 2 g (see Supporting Information for optimization details). Other 4-methyl substituted coumarins followed the same trend: dcype outperformed P(nBu)3. An EOM-protected hymecromone gave 58% of 2i, the structure of which was further confirmed by X-ray crystallography.[35] Protected 4-methylesculetin also gave 71% of the boron isostere 2j. Similarly, another non-natural coumarin 2k can be transformed into boron-containing products. It is worth mentioning that 3-methyl substituted coumarin also gave a better yield of 2l with dcype than with P(nBu)3. The decarbonylative borylation on 4-aryl substituted similarly favored dcype as the preferred ligand. Both electron-rich and electron-deficient aryl substituents on C4 could be tolerated (2m–2p). Benzocoumarins are viable substrates for this protocol as well. The preference of ligands is in accordance with that of 4-substituted coumarins, in which dcype is more suitable for the reaction. A benzocoumarin with a π-extended system also gave a 55% yield of the product 2r. An effect of protecting groups on yields was also observed. In particular, the methyl-protected urolithin B gave a 44% yield of the dibenzoxaborin 2 s, while the EOM-protected one gave a 49% yield of 2t. In contrast, the methyl-protected umbeliferone gave a better yield than the EOM-protected derivative. In addition, the C-to-B swap method was successfully applied to access the 7-membered dibenzoxaborepins, which, to the best of our knowledge, have not been reported in the literature. Without modifying the reaction conditions, 7-membered dibenzolactones with electron-rich and electron-deficient substituents were transformed into the corresponding cyclic boronic hemiesters 2u–2y in 31%–79% yields. The ligand preference in such substrates was not as prominent as in the cases of coumarin. An X-ray crystal structure of 2w was obtained, which confirms that it exists as a cyclic boronic hemiester.[35]

We next sought to engage oxaborins as synthetic intermediates in new transformations. The Yorimitsu group demonstrated that oxaborins can undergo Suzuki–Miyaura cross-coupling reactions with iodobenzene to give predominantly Z-alkenes.[10] We saw an opportunity to combine this C–C bond formation with a C–O bond-forming reaction in one pot. This tandem reaction successfully transformed oxaborin 2a to oxazepin 4 in > 99% yield using a Pd/BrettPhos catalyst, indicating retention of the Z-alkene configuration under these reaction conditions (Figure 5a).

Figure 5.

Figure 5.

Applications of C-to-B swap. a) Arene insertion into the oxaborin intermediate; and b) editing polyaromatic hydrocarbons. a)Yield of a 2.00 mmol scale reaction.

Finally, inspired by strong interest in accessing boron-doped polyaromatic hydrocarbons for their optical properties,[16,18,36–38] we questioned whether these molecules can be accessed from their all carbon isosteres through a series of atom-swapping reactions. In this vein, we accomplished a “C-to-O” swap on phenanthrene 5 by oxidation to the lactone 1q by oxone in one step in 62% yield (Figure 5b).[39] Using the decarbonylative borylation reaction we developed, a “C-to-B” swap on 2.0 mmol scale then converted 1q to 2q in 47% yield without modification of our standard conditions. Further molecular editing of the two-dimensional polyaromatic hydrocarbon core using the arene insertion conditions we developed for 2a then gave the heterocycles 6 and 7 containing the tribenzo[b.d.f]oxepine framework for which few synthetic methods exist.[40,41] Collectively, the transformation of 1a to oxepins and 5 to tribenzoxepines further advances the synthetic utility of cyclic boronic hemiesters.

A mechanistic question that we wish to answer is why P(nBu)3 outperforms dcype for 4-H coumarin substrates 2a–2e while the opposite is true for 4-methyl and 4-aryl substituted derivatives 2g–2l. We first explored an alternative mechanism, which involves the formation of benzofuran, followed by boron insertion into the benzofuran reported by Yorimitsu and coworkers.[10] A later report also demonstrated that this chemistry is viable with several electron-rich phosphines.[21] Competition studies between a benzofuran and a coumarin with a similar backbone (3 vs. 2b, and 4 vs. 2h, Figure 6a) showed a large conversion to the coumarin-related benzoxaborin but very little conversion to the benzofuran-related product. The inferior performance of the benzofuran substrates shows that the mechanism involving the borylation of benzofuran is unlikely to be the major reaction pathway.

Figure 6.

Figure 6.

Mechanistic study: a) Competition experiments between coumarin and benzofuran substrate. b) Formation of nickelacycles between Ni-dcype and different coumarin substrates.

A series of stoichiometric reactions without the bisboron reagent revealed the formation of a nickelacycle species dcype-Ni-I arising from strong back-donation of the Ni complex to the C3=C4 bond of the coumarin.[42] We observed that nickelacycle formation occurred more readily with coumarin 1a compared to coumarins with 4-substituents (Figure 6b, entry 1 vs. entries 2 and 3). This observation aligns with the trend in yields of 2a<<2g < 2m (Figure 4) with the Ni/dcype system, suggesting that substrate 1a contributes to catalyst deactivation when dcype ligand is used. In contrast, the Ni–P(nBu)3 catalyst exhibited minimal substrate dependence in nickelacycle formation—1a, 1g, and 1m underwent quantitative conversion to the corresponding nickelacycle species. Furthermore, the rate of nickelacycle formation is significantly different for dcype and P(nBu)3 (2 days vs. 30 min, see Section S4.1). Based on these results, we speculate that the mechanism is more complicated than what is initially depicted in Figure 2b and may involve the nickelacycle as an off-cycle species. Consequently, the catalyst resting state and therefore the detailed mechanism of the reaction may be different for each ligand and substrate.

In conclusion, we have achieved a C-to-B atom-swapping reaction via Ni-catalyzed decarbonylative borylation to transform a variety of coumarins and benzocoumarins into their boron isosteres in one step. The same catalytic reaction can be applied to dibenzolactones to generate rare 7-membered cyclic boronic hemiesters. We further utilized the new cyclic boronic hemiesters to access medium-ring oxygen heterocycles for which few synthetic methods exist. Finally, our preliminary investigations into the molecular editing of polyaromatic hydrocarbons demonstrate that C-to-O and C-to-B atom swapping reactions can be utilized to transform these hydrocarbons into valuable boron-doped heterocycles and new three-dimensional architectures.

Supplementary Material

SI file 1
cif files

Additional supporting information can be found online in the Supporting Information section

Acknowledgements

The authors acknowledge Dr. Arkady Ellern for X-ray crystallographic analyses of compound 2i and 2w as well as the W. M. Keck Metabolomics Research Laboratory (Iowa State University) for mass spectrometry analyses of all new compounds. The authors thank the National Institutes of Health for financial support (R35GM146854). The authors also thank Iowa State University for start-up funds and a postdoctoral seed grant award to Q.H.L. The authors thank Udayan Chaudhury and Liang-Yu Chen (both from Iowa State University) for checking experimental procedures.

Footnotes

Conflict of Interests

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available in the Supporting Information of this article.

References

  • [1].Strynadka NCJ, Martin R, Jensen SE, Gold M, Jones JB, Nat. Struct. Biol 1996, 3, 688–695. [DOI] [PubMed] [Google Scholar]
  • [2].Diaz DB, Yudin AK, Nat. Chem 2017, 9, 731–742. [DOI] [PubMed] [Google Scholar]
  • [3].Rock FL, Mao W, Yaremchuk A, Tukalo M, Crépin T, Zhou H, Zhang Y-K, Hernandez V, Akama T, Baker SJ, Plattner JJ, Shapiro L, Martinis SA, Benkovic SJ, Cusack S, Alley MRK, Science 2007, 316, 1759–1761. [DOI] [PubMed] [Google Scholar]
  • [4].Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Clifton MC, Atkins K, Raymond A, Potts KT, Abendroth J, Boyer SH, Loutit JS, Morgan EE, Durso S, Dudley MN, J. Med. Chem 2015, 58, 3682–3692. [DOI] [PubMed] [Google Scholar]
  • [5].Hecker SJ, Reddy KR, Lomovskaya O, Griffith DC, Rubio-Aparicio D, Nelson K, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Parkinson J, Totrov M, Boyer SH, Glinka TW, Pemberton OA, Chen Y, Dudley MN, J. Med. Chem 2020, 63, 7491–7507. [DOI] [PubMed] [Google Scholar]
  • [6].Das BC, Adil Shareef M, Das S, Nandwana NK, Das Y, Saito M, Weiss LM, Bioorg. Med. Chem 2022, 63, 116748. [DOI] [PubMed] [Google Scholar]
  • [7].He J, Crase JL, Wadumethrige SH, Thakur K, Dai L, Zou S, Rathore R, Hartley CS, J. Am. Chem. Soc 2010, 132, 13848–13857. [DOI] [PubMed] [Google Scholar]
  • [8].Mathew SM, Engle JT, Ziegler CJ, Hartley CS, J. Am. Chem. Soc 2013, 135, 6714–6722. [DOI] [PubMed] [Google Scholar]
  • [9].Zhou QJ, Worm K, Dolle RE, J. Org. Chem 2004, 69, 5147–5149. [DOI] [PubMed] [Google Scholar]
  • [10].Saito H, Otsuka S, Nogi K, Yorimitsu H, J. Am. Chem. Soc 2016, 138, 15315–15318. [DOI] [PubMed] [Google Scholar]
  • [11].Tsuchiya S, Saito H, Nogi K, Yorimitsu H, Org. Lett 2017, 19, 5557–5560. [DOI] [PubMed] [Google Scholar]
  • [12].Körner C, Starkov P, Sheppard TD, J. Am. Chem. Soc 2010, 132, 5968. [DOI] [PubMed] [Google Scholar]
  • [13].Dewar MJS, Dietz R, Tetrahedron Lett. 1959, 1, 21–23. [Google Scholar]
  • [14].Dewar MJS, Dietz R, J. Chem. Soc 1960, 1960, 1344. [Google Scholar]
  • [15].Paetzold P, Stanescu C, Stubenrauch JR, Bienmüller M, Englert U, Z. Anorg. Allg. Chem 2004, 630, 2632–2640. [Google Scholar]
  • [16].Budanow A, von Grotthuss E, Bolte M, Wagner M, Lerner H-W, Tetrahedron 2016, 72, 1477–1484. [Google Scholar]
  • [17].Sumida Y, Harada R, Kato-Sumida T, Johmoto K, Uekusa H, Hosoya T, Org. Lett 2014, 16, 6240–6243. [DOI] [PubMed] [Google Scholar]
  • [18].Ouadoudi O, Kaehler T, Bolte M, Lerner H-W, Wagner M, Chem. Sci 2021, 12, 5898–5909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [19].Benhamou L, Walker DW, Bučar D-K, Aliev AE, Sheppard TD, Org. Biomol. Chem 2016, 14, 8039–8043. [DOI] [PubMed] [Google Scholar]
  • [20].Guo R, Li K-N, Liu B, Zhu H-J, Fan Y-M, Gong L-Z, Chem. Commun 2014, 50, 5451–5454. [DOI] [PubMed] [Google Scholar]
  • [21].Boyer SH, Gonzalez-de-Castro A, Dielemans JAH, Lefort L, Zhu Z, Gnahn M, Schörghuber J, Steinhofer S, de Vries AHM, Hecker SJ, Org. Process Res. Dev 2022, 26, 925–935. [Google Scholar]
  • [22].Chen J, Bajko Z, Kampf JW, Ashe AJ, Organometallics 2007, 26, 1563–1564. [Google Scholar]
  • [23].Yruegas S, Patterson DC, Martin CD, Chem. Commun 2016, 52, 6658–6661. [DOI] [PubMed] [Google Scholar]
  • [24].Long A, Liu CY, Liu C, Zhou Y, Pulley SR, Graham KAN, WO 2022133420 A1 2022.
  • [25].Dictionary of Natural Products Database, https://dnp.chemnetbase.com/ (accessed: April 2025).
  • [26].Bouhaoui A, Eddahmi M, Dib M, Khouili M, Aires A, Catto M, Bouissane L, ChemistrySelect 2021, 6, 5848–5870. [Google Scholar]
  • [27].Zhang Y, Lu H, Chang J, Xu P-F, Li H, Jin Y, Wei H, Angew. Chem. Int. Ed 2025, 64, e202500921. [DOI] [PubMed] [Google Scholar]
  • [28].Luu QH, Li J, Chem. Sci 2022, 13, 1095–1100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [29].Malapit CA, Borrell M, Milbauer MW, Brigham CE, Sanford MS, J. Am. Chem. Soc 2020, 142, 5918–5923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30].Malapit CA, Bour JR, Laursen SR, Sanford MS, J. Am. Chem. Soc 2019, 141, 17322–17330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [31].Thomas AA, Zahrt AF, Delaney CP, Denmark SE, J. Am. Chem. Soc 2018, 140, 4401–4416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [32].Pu X, Hu J, Zhao Y, Shi Z, ACS Catal. 2016, 6, 6692–6698. [Google Scholar]
  • [33].Guo L, Rueping M, Chem. - Eur. J 2016, 22, 16787–16790. [DOI] [PubMed] [Google Scholar]
  • [34].U.S. FDA Food Ingredients and Packaging, https://www.fda.gov/food/food-ingredients-packaging (accessed: April 2025).
  • [35].Deposition numbers 2211749 (for 2i) and 2211750 (for 2v) contain the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service.
  • [36].Gu Y, Muñoz-Mármol R, Fan W, i Han Y, Wu S, Li Z, Bonal V, Villalvilla JM, Quintana JA, Boj PG, Díaz-García MA, Wu J, Adv. Opt. Mater 2022, 10, 2102782. [Google Scholar]
  • [37].Guo Y, Zhang L, Li C, Jin M, Zhang Y, Ye J, Chen Y, Wu X, Liu X, J. Org. Chem 2021, 86, 12507–12516. [DOI] [PubMed] [Google Scholar]
  • [38].Romanenkoa VD, Sotiropoulos J-M, in Comprehensive Heterocyclic Chemistry IV (Ed: Gharpure SJ), Vol. 9, Elsevier, Amsterdam: 2022, pp. 806–845. [Google Scholar]
  • [39].Parida KN, Moorthy JN, J. Org. Chem 2015, 80, 8354–8360. [DOI] [PubMed] [Google Scholar]
  • [40].Dobelmann L, Parham AH, Büsing A, Buchholz H, König B, RSC Adv. 2014, 4, 60473–60477. [Google Scholar]
  • [41].Dimitrijević E, Cusimano M, Taylor MS, Org. Biomol. Chem 2014, 12, 1391–1394. [DOI] [PubMed] [Google Scholar]
  • [42].Fischer R, Rudolph M, Uhlig E, Z. Anorg. Allg. Chem 1985, 520, 93–106. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

SI file 1
cif files

Data Availability Statement

The data that support the findings of this study are available in the Supporting Information of this article.

RESOURCES